July 26, 2014 2:12 PM ET

Pharmaceuticals

Company Overview of MiddleBrook Pharmaceuticals, Inc.

Company Overview

As of January 3, 2011, MiddleBrook Pharmaceuticals, Inc. went out of business. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products using its proprietary delivery technology, PULSYS in the United States. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections, and upper respiratory tract infections. It sells its products directly to wholesalers, and food and drug chains. The company was formerly known as Advancis Pharmaceutical Corporation and changed its name to MiddleBrook Pharmaceutical...

7 Village Circle

Suite 100

Westlake, TX 76262

United States

Founded in 1999

22 Employees

Phone:

817-837-1200

Fax:

817-582-0400

Key Executives for MiddleBrook Pharmaceuticals, Inc.

MiddleBrook Pharmaceuticals, Inc. does not have any Key Executives recorded.

MiddleBrook Pharmaceuticals, Inc. Key Developments

SEC Orders Hearings On Registration Suspension Or Revocation Against MiddleBrook Pharmaceuticals, Inc. For Failure To Make Required Periodic Filings

Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of MiddleBrook Pharmaceuticals, Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.

Similar Private Companies By Industry

Company Name Region
Liddell Laboratories, Inc. United States
H. Bana Ltd. United States
Araios, Inc. United States
Ajinomoto AminoScience LLC United States
Chelated Minerals Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MiddleBrook Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.